30 results about "Prostaglandin D2 receptor" patented technology

The present invention relates to (3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives of Formula (I) wherein R1, R2, R3, R4, R5 and R6 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

The present invention relates to 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives of the formula (I),wherein R1, R2, R3 and R4 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

The present invention relates to 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives of the formula (I),wherein R1, R2 and R3 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.

Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both.

The present invention is directed to a substituted pyrimidine compound of formula (I) as set forth herein, or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound. Formula (I), wherein m and n, independently of each other, are selected from the integers 0, 1, 2 or 3; X and Y, independently of each other, are selected from CRR, NR or O, wherein X and Y cannot both be O; or X and Y, taken together with the bond between them, form a phenyl group optionally substituted by one to four R groups; each Z, independently of each other, is CRR; R, R and R, independently of each other, are selected from the group consisting of H, halogen, aryl, amino, optionally substituted alkyl, optionally substituted alkoxy, and carboxy; wherein optionally substituted alkyl, may be substituted by one to three of the same or different of halogen, carboxy, cyano, hydroxy, amino or aryl.

The present invention relates to azaindolle acetic acid derivatives of formula (I),wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

The present invention is directed to the dihydrogen phosphate salt of 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

The present invention is directed to a 2,6-substituted-4-monosubstitutedamino-pyrinudine compound of formula (I) as set forth herein, or an enantiomer thereof, or an ester prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.

The present invention relates to phenyl-substituted heterocyclic derivatives of formula (I), wherein Z, n, m, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 as described herein, and as prostaglandin receptor modulators, most particularly as prostaglandin D 2 Use of receptor modulators in treating various prostaglandin-mediated diseases and conditions, pharmaceutical compositions containing these compounds and preparation methods thereof.

The invention provides a simple preparation method of a prostaglandin D2 receptor inhibitor compound. The compound is obtained by using 4-methylsulfonyl-2-trifluoromethylbenzylamine (II) and 3-acetylglutaric acid diester (III) as raw materials, carrying out condensation and cyclization, carrying out an addition reaction with 2-halogenated acrolein, carrying out a pyridine cyclization reaction withammonia and finally carrying out hydrolysis and hydrochloric acid acidification. The method of the invention has the advantages of simple operation, mild reaction conditions, less three wastes, environmental protection, cheap and easily available raw materials, low cost, high reaction selectivity, less by-products, simple purification and high yield and purity, and facilitates the industrial production of the prostaglandin D2 receptor inhibitor compound Fevipiprant.

The invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.

The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I),wherein Y, Z, R1, R2, R3 and R4 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I) wherein Z, n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

This invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.